ANI Pharmaceuticals
ANIP
171 hedge funds and large institutions have $662M invested in ANI Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 72 increasing their positions, 25 reducing their positions, and 11 closing their positions.
300% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 11
263% more capital inflows, than outflows
Capital inflows: $119M | Capital outflows: $32.8M
188% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 25
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
24% more funds holding
Funds holding: 138 → 171 (+33)
22% more call options, than puts
Call options by funds: $1.46M | Put options by funds: $1.2M
1.69% more ownership
Funds ownership: 59.4% → 61.09% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
+$22.8M |
| 2 |
RIM
Ranger Investment Management
Dallas,
Texas
|
+$14.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10.6M |
| 4 |
Rubric Capital Management (New York)
New York
|
+$8.82M |
| 5 |
BlackRock
New York
|
+$8.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Emerald Advisers
Leola,
Pennsylvania
|
-$8.83M |
| 2 |
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$7.14M |
| 3 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
-$6.65M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$1.93M |
| 5 |
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$1.4M |
ANIP Hedge Fund Activity: Q2 2023 in Review
171 of the 6,387 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q2 2023, worth a combined $662M — up 61% from $412M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new ANIP positions and 11 closed out — a net gain of 33 holders — while 72 added to existing stakes and 25 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $22.8M. The largest seller was Emerald Advisers, cutting an estimated $8.83M.
- 171 institutional investors held ANI Pharmaceuticals (ANIP) as of Q2 2023, up from 138 in Q1 2023.
- Funds reported $662M of ANI Pharmaceuticals stock for Q2 2023, up 61% quarter-over-quarter.
- 44 funds opened new ANI Pharmaceuticals positions in Q2 2023 and 11 closed out, a net change of +33 holders.
- The largest ANI Pharmaceuticals buyer in Q2 2023 was Deep Track Capital, an estimated $22.8M added.
- The largest ANI Pharmaceuticals seller in Q2 2023 was Emerald Advisers, an estimated $8.83M sold.
Based on aggregated 13F filings for Q2 2023.